Share Prices & Company Research

Market News

25 Feb 2021 | 15:01

Merck to buy Pandion Therapeutics for $1.85bn

(Sharecast News) - Merck has agreed to buy clinical-stage biotechnology company Pandion Therapeutics for $1.85bn.

Under the terms of the deal, Merck will pay $60 per share in cash for Pandion, which is developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases.

Dr. Dean Y. Li, president of Merck Research Laboratories, said: "This acquisition builds upon Merck's strategy to identify and secure candidates with differentiated and potentially foundational characteristics.

"Pandion has applied its TALON technology to develop a robust pipeline of candidates designed to re-balance the immune response with potential applications across a wide array of autoimmune diseases."

The transaction is expected to close in the first half of the year.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.